Drug intelligence / Profile preview

diphtheria + tetanus + pertussis (acellular, component) vaccine (adsorbed)

Development stage
Phase 4
Lead developer
Beijing Minhai Biological
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

This vaccine is a trivalent combination product designed to provide active immunization against diphtheria, tetanus, and pertussis. Developed by Beijing Minhai Biotechnology, it is the first "component" DTaP vaccine produced domestically in China. Unlike traditional acellular pertussis vaccines that use co-purified antigens, this component vaccine contains individually purified and precisely quantified antigens, specifically pertussis toxoid (PT) and filamentous hemagglutinin (FHA), along with diphtheria and tetanus toxoids. The antigens are adsorbed onto an aluminum hydroxide adjuvant to enhance the immune response. It is indicated for primary and booster vaccination in infants and children to prevent infections caused by *Corynebacterium diphtheriae*, *Clostridium tetani*, and *Bordetella pertussis*.

Other names
DTaP (component) vaccineDTaP-cp vaccineadsorbed acellular diphtheria, tetanus and pertussis (component) combined vaccine
02

Targets

Diphtheria toxinFHA (Filamentous hemagglutinin)

Beyond the preview

Go deeper on diphtheria + tetanus + pertussis (acellular, component) vaccine (adsorbed).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diphtheria + tetanus + pertussis (acellular, component) vaccine (adsorbed).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call